内部编号:2025060183 上海荣泰健康科技股份有限公司 公开发行可转换公司债券 定期跟踪评级报告 | 项目负责人: | 黄梦姣 | 品,男女 | hm j@shxs j. com | | --- | --- | --- | --- | | 翁斯詰 | | 12557 85 | wsz@shxsj.com | | 项目组成员: | | | | | 评级总监: | 张明海 | 82-16 | | | 联系电话:(021)63501349 | | | | | 联系地址:上海市黄浦区汉口路 398 号华盛大厦 14 层 | | | | | 公司网站:www.shxsj.com | | | | 上海新世纪资信评估投资服务有限公司 Shanghai Brilliance Credit Rating & Investors Service Co. . Ltd. 声明 除因本次评级事项使本评级机构与评级对象构成委托关系外,本评级机构、评级人员与评级对象不存在任何影响 评级行为独立、客观、公正的关联关系。 本评级机构与评级人员履行了调查和诚信义务,所出具的评级报告遵循了真实、客观、公正的原则。 本报告的评级结论是本评级机 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-042 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，并书面征询了公 司控股股东及实际控制人，现将有关情况说明如下： 重要内容提示： 上海荣泰健康科技股份有限公司（以下简称"公司"）股票于 2025 年 6 月 17 日、2025 年 6 月 18 日、2025 年 6 月 19 日连续三个交易日内日收盘价格涨 幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股 票交易异常波动。公司郑重提醒广大投资者注意交易风险，审慎决策，理性投资。 经公司自查并书面征询公司控股股东及实际控制人，截至本公告披露日， 除公司已披露事项外，不存在应披露而未披露的重大信息。 一、股票交易异常波动的具体情况 公司股票 ...

Core Viewpoint - The A-share market experienced a weak and fluctuating trend, with the three major indices showing mixed performance, while the brain-computer interface concept stocks surged [1] Market Performance - The Shanghai Composite Index fell by 0.19% - The Shenzhen Component Index remained flat - The ChiNext Index decreased by 0.14% - The total trading volume in the Shanghai and Shenzhen markets was 771.5 billion, a decrease of 16.6 billion compared to the previous trading day [1] Sector Highlights - The brain-computer interface concept stocks were notably active, with companies such as Aipeng Medical, Nanjing Panda, Innovation Medical, and Rongtai Health hitting the daily limit [1] - Oil and gas stocks opened lower but rebounded, while stablecoin concepts and battery sectors showed significant gains [1] - The film and television industry, weight loss drugs sector, and IP economy experienced declines, with Harsco hitting the daily limit down [1]

Core Insights - The smart home industry is accelerating towards intelligence, greenness, and globalization, driven by AI technology [1][3] Group 1: AI Empowerment Across Industries - The smart terminal industry is undergoing a profound transformation driven by AI technology, with companies like Hisense leading the way in integrating display technology and AI interaction [3] - Hisense has developed RGB Mini LED liquid crystal modules and AI quality chips, enhancing color coverage and reducing energy consumption [3] - Rongtai Health integrates AI throughout its health services, using AI algorithms in massage chairs to create personalized experiences and improving production efficiency through AI industrial systems [3] - Sichuan Changhong is implementing AI across product development, manufacturing, and management, enhancing operational efficiency and reducing costs [4] - Jinhai High-Tech is advancing digital transformation through a comprehensive digital workshop management system and predictive maintenance using IoT technology [4] - Wanlong Magnetic Plastic is embracing the transformation in the home appliance industry by increasing R&D investment to enhance innovation capabilities [4] Group 2: Global Expansion Strategies - The globalization of China's home appliance industry presents opportunities for suppliers with international layouts, as highlighted by Wanlong Magnetic Plastic's expansion into 10 countries with 16 production bases by the end of 2024 [5] - Rongtai Health is enhancing global supply chain resilience with a new factory in Thailand expected to be operational by the end of 2025, while also strengthening partnerships with clients in the U.S. and other regions [5] - Sichuan Changhong has established R&D bases in the U.S., Spain, and the Czech Republic, and manufacturing bases in Mexico and Vietnam, aiming for coordinated development across the entire value chain [5] - Jinhai High-Tech has set up R&D and marketing centers in Thailand and Japan, achieving overseas revenue of 459 million yuan in 2024, a year-on-year increase of 16.99% [6] - Hisense is advancing its global strategy by enhancing product quality and brand influence through major sporting events and collaborations with various brands [6]

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-041 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | （一）现金管理目的 在确保不影响募集资金安全、不改变募集资金用途和募集资金投资项目资金 使用进度安排的前提下，利用部分可转债闲置募集资金进行现金管理，最大限度 地提高公司募集资金的使用效率，为公司和股东谋取较好的财务性收益。 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金现金管理赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：可转让大额存单 投资金额：人民币 3,000 万元 现金管理期限：持有该存单期限不超过 12 个月 已履行的审议程序：上海荣泰健康科技股份有限公司（以下简称"公司"） 于 2025 年 4 月 23 日召开第四届董事会第二十一次会议、第四届监事会第十 六次会议，于 2025 年 5 月 14 日召开 2024 年年度股东大会，分别审议通过 了《关于公司 ...

Core Viewpoint - The company is utilizing idle funds from convertible bonds for cash management to enhance financial returns while ensuring the safety and intended use of the raised funds [1][5]. Summary by Sections Cash Management Overview - The purpose of cash management is to maximize the efficiency of the raised funds and provide better financial returns for the company and its shareholders, without affecting the safety and intended use of the funds [2][5]. - The amount used for cash management is RMB 30 million, invested in a high-security, liquid, low-risk large-denomination certificate of deposit [2][3]. - The funds are sourced from the public issuance of convertible bonds, which raised a total of RMB 600 million, with a net amount of RMB 593.98 million after expenses [2][3]. Investment Details - The investment type is a large-denomination certificate of deposit, with an investment amount of RMB 30 million and a maximum holding period of 12 months [3][4]. - The company has received approval from its board and supervisory board for the cash management plan, allowing the use of up to RMB 450 million of idle funds for safe and liquid financial products [3][5]. Impact on the Company - The cash management initiative is expected to improve the company's investment returns and fund utilization efficiency without impacting its main business operations or the progress of investment projects [5][6]. - The company does not have significant debt obligations that would affect its ability to manage these funds effectively [6].

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-041 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金现金管理赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：可转让大额存单 投资金额：人民币 3,000 万元 现金管理期限：持有该存单期限不超过 12 个月 已履行的审议程序：上海荣泰健康科技股份有限公司（以下简称"公司"） 于 2025 年 4 月 23 日召开第四届董事会第二十一次会议、第四届监事会第十 六次会议，于 2025 年 5 月 14 日召开 2024 年年度股东大会，分别审议通过 了《关于公司 2025 年度使用可转债闲置募集资金进行现金管理的议案》， 同意公司及子公司使用最高不超过人民币 4.5 亿元的公开发行可转换公司债 券（以下简称"可转债"）闲置募集资金适时投资安全性高、流动性好、低风 险的理财产品或结构性存 ...

Core Viewpoint - Shanghai Rongtai Health Technology Co., Ltd. announced its 2024 annual profit distribution plan, proposing a cash dividend of RMB 3.50 per 10 shares (including tax) to all shareholders, with the total cash dividend amount adjusted to RMB 61,282,903.85 (including tax) due to changes in the total share capital from convertible bond conversions [2][13][16]. Distribution Plan - The distribution year is set for 2024, and the distribution will be made to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the registration date [3]. - The company will not issue bonus shares or increase capital reserves, and any undistributed profits will be carried forward to future years [4][13]. Dividend Calculation - The cash dividend per share is calculated as follows: (175,094,011 shares participating in distribution × RMB 0.35) ÷ 177,397,211 total shares ≈ RMB 0.3455 per share [6][16]. - The reference price for ex-dividend trading will be adjusted based on the formula: (previous closing price - cash dividend) [5][6]. Tax Implications - For individual shareholders holding unrestricted shares, dividends are subject to different tax treatments based on the holding period, with a maximum tax rate of 20% for shares held for less than one month [8][10]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply to dividends [10]. Convertible Bond Adjustment - The conversion price for the company's convertible bonds ("Rongtai Convertible Bonds") will be adjusted from RMB 23.42 per share to RMB 23.07 per share due to the cash dividend distribution [19][24]. - The adjustment will take effect on June 12, 2025, and the bonds will stop conversion from June 5 to the registration date [24].

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-039 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于利润分配调整"荣泰转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因实施权益分派,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 113606 | 荣泰转债 | 可转债转股复 | | | 2025/6/11 | 2025/6/12 | | | | 牌 | | | | | 上海荣泰健康科技股份有限公司（以下简称"公司"）于 2020 年 10 月 30 日 公开发行 600 万张可转换公司债券，每张面值 100 元，发行总额 60,000.00 万元， 期限 6 年，并于 2020 年 11 ...

上海市广发律师事务所 关于上海荣泰健康科技股份有限公司 差异化分红事项之 专项法律意见 电话：021-58358013 | 传真：021-58358012 网址：http://www.gffirm.com | 电子信箱：gf@gffirm.com 办公地址：上海市浦东新区南泉北路 429 号泰康保险大厦 26 层 | 邮政编码：200120 上海市广发律师事务所 2 随其他需公告的信息一起向公众披露，本所依法对发表的法律意见承担责任。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神发表意见如下： 关于上海荣泰健康科技股份有限公司差异化分红事项之 专项法律意见 致：上海荣泰健康科技股份有限公司 上海市广发律师事务所（以下简称"本所"）接受上海荣泰健康科技股份有 限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所上市公司自律监管指引第 7 号——回购股份》（以下简称"《自 律监管指引第 7 号》"）等法律法规、其他规范性文件以及《上海荣泰健康科技 股份 ...